Vernal is proud to be the Silver Sponsor for this exciting event! Connect with one of Vernal’s experts on November 8-10, 2022 in Boston and meet them at our booth. We want to know about your mRNA and LNP projects,…
Vernal Biosciences is excited to announce the start of construction on its new, 23,000 square foot mRNA manufacturing facility in Essex Junction, Vt. The new facility will include state-of-the-art equipment and clean rooms to support clinical mRNA and LNP mRNA…
Local NBC affiliate NBC5 came to visit Vernal Bioscience to discuss the eventual move to a new, larger facility in Essex and our plans to nearly quadruple our workforce. Watch the story on NBC5.
Vernal produces high-purity mRNA to supply to companies that develop mRNA-based health treatments. Read the full story at VTDigger.
Vernal Biosciences has received $21 million from investors and is expanding to a new laboratory in Essex next year.
Vernal Biosciences has raised $21 million to build a manufacturing facility in Essex that will scale up the business from supporting research to being involved in clinical trials.
Vernal Biosciences announced today the completion of a $21 million financing to fully integrate its mRNA manufacturing solutions.
We are excited to announce the addition of two new members to the Vernal team: Scott Vanson, Ph.D. and JJ Bivona, Ph.D.
Vernal Biosciences has been awarded a $99,475 grant from the Vermont Training Program (VTP).
We recently completed a biodistribution study of lipid nanoparticles containing mRNA encoding luciferase in mice.
Vernal Biosciences, the Colchester-based manufacturer of mRNA used in cutting-edge medicines, plans to nearly triple the size of its staff, from 12 to 35, using a grant from the Vermont Training Program. Read the full story here.
Vernal Biosciences in Colchester helps make mRNA, which acts as a kind of roadmap a cell uses to make a specific protein.